Emit Imaging
About Emit Imaging
Emit Imaging utilizes Cryo-Fluorescence Tomography (CFT) to provide high-resolution, three-dimensional imaging of drug distribution and protein expression in whole animals. This technology enhances preclinical research by enabling precise visualization of biodistribution and therapeutic effects, addressing the limitations of traditional 2D imaging methods.
```xml <problem> Traditional 2D in vivo fluorescence imaging techniques lack the ability to visualize the whole-body distribution of drugs and therapeutic proteins, limiting the understanding of on- and off-target effects during preclinical research. Existing whole-body techniques like MRI, PET, and SPECT offer lower resolution and sensitivity compared to cellular microscopy, creating a gap in imaging capabilities. </problem> <solution> Emit Imaging provides Cryo-Fluorescence Tomography (CFT) through its Xerra™ imaging platform, enabling high-resolution, three-dimensional visualization of drug distribution and protein expression in whole animals. CFT bridges the gap between cellular microscopy and lower-resolution whole-body imaging techniques, allowing researchers to monitor biodistribution, expression, and biochemical processes with greater precision. The platform automates the CFT workflow, involving cryo-preservation, serial sectioning, high-resolution imaging of each section, and 3D reconstruction to generate comprehensive volumetric data. This approach facilitates a more complete understanding of drug delivery, target engagement, and potential off-target effects. </solution> <features> - Automated Cryo-Fluorescence Tomography (CFT) workflow for in-house sample processing - High-resolution, high-sensitivity white light and fluorescence imaging - Serial sectioning with removal of 20-55 micron sections - 3D image stack generation with overlay of white light and fluorescence data - Visualization of whole-body drug distribution and delivery - Screening of candidate drugs and delivery systems - Monitoring of whole-body therapeutic protein expression - Multiplexed co-localization of drug with targets - Identification of on- and off-target tissue - Fee-for-service CFT research performed in-house </features> <target_audience> The primary target audience includes researchers in drug discovery and development, oncology, immunotherapy, gene and cell therapy, and neuroscience who require detailed, quantitative data on drug distribution and protein expression in preclinical animal models. </target_audience> ```
What does Emit Imaging do?
Emit Imaging utilizes Cryo-Fluorescence Tomography (CFT) to provide high-resolution, three-dimensional imaging of drug distribution and protein expression in whole animals. This technology enhances preclinical research by enabling precise visualization of biodistribution and therapeutic effects, addressing the limitations of traditional 2D imaging methods.
Where is Emit Imaging located?
Emit Imaging is based in Baltimore, United States.
When was Emit Imaging founded?
Emit Imaging was founded in 2018.
How much funding has Emit Imaging raised?
Emit Imaging has raised 18730000.
- Location
- Baltimore, United States
- Founded
- 2018
- Funding
- 18730000
- Employees
- 21 employees